We use press releases to update external stakeholders on our progress. We want to make sure you have all the information you need to provide comprehensive feedback on our reports.
Subscribers can expect to receive press releases at the following milestones: Topic Announcement, Draft Evidence Report, Revised Evidence Report, and Final Evidence Report.
You can also find the week’s press releases in our newsletter.
For any questions, please contact mediainquiries@icer.org.
Sign up for our Press Releases and Newsletter!
Subscribe now!
Featured Press Releases
ICER Releases Draft Evidence Report on Gene Therapies for Hemophilia A and B
Public comment period now open until October 11, 2022; Requests to make oral comment during public meeting also being accepted.
09/13/2022ICER Publishes Final Evidence Report and Policy Recommendations on Treatments for Amyotrophic Lateral Sclerosis
Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral edaravone (in population narrower than its label) provide a net health benefit compared to standard of care; also determined that at current pricing or price estimates both therapies represent a “low” long-term value for money.
09/13/2022ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020